RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Purpose

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Condition

  • Generalized Anxiety Disorder

Eligibility

Eligible Ages
Between 18 Years and 74 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Has Generalized Anxiety Disorder as defined by DSM-5-TR - If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant. - Is willing and able to comply with the conditions and requirements of the study

Exclusion Criteria

  • Has a significant risk of suicide - Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder - Has other concurrent psychiatric disorders that is the primary disorder. - Has other medically significant conditions rendering unsuitability for the study - Has used or will need to use prohibited medications or therapies - Has a known sensitivity or intolerance to study intervention or potential rescue medications

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Placebo Comparator
Placebo
A single subcutaneous injection of 0.9% sodium chloride for injection
  • Drug: Placebo
    Single, subcutaneous dose of 0.9% sodium chloride for injection
Experimental
30 mg RE104
A single subcutaneous injection of 30 mg RE104 for Injection
  • Drug: RE104 for Injection
    Single, subcutaneous dose of RE104 for Injection

Recruiting Locations

Lighthouse Psychiatry
Gilbert, Arizona 85234
Contact:
Matt Longson
435-268-5800
Contact@neosciclinicalresearch.com

Open Mind Therapeutics
San Francisco, California 94114
Contact:
Victoria Vega
415-906-7399
victoria@openmindcollective.org

TRIP Clinic at Psychedelic Science Institute
Santa Monica, California 90404
Contact:
Ashley Ramos
trialadmin@psychedlicsci.com

University of South Florida
Tampa, Florida 33613
Contact:
Genesis Estramera
813-974-1404
gestramera@usf.edu

Atlanta Center for Medical Research
Atlanta, Georgia 30331
Contact:
Amber Tannahill
404-881-5800
a.tannahill@cenexel.com

CenExel iResearch, LLC
Decatur, Georgia 30030
Contact:
Michael Mahaffrey
m.mahaffrey@cenexel.com

UNM Research Program Psychedelic Therapies
Albuquerque, New Mexico 14624
Contact:
Hector Garcia
505-675-0582
hecgarcia@salud.unm.edu

Summit Headlands LLC
Portland, Oregon 97210
Contact:
Tyler Leecing
tyler.leecing@summitnetwork.com

Austin Clinical Trial Partners
Austin, Texas 78737
Contact:
Kara Chilek
512-521-0595
studyinfo@austinCTP.com

Aim Trials, LLC
Plano, Texas 75093
Contact:
Sonia Prashar
214-856-2778
sonia.prashar@aimtrials.com

Cedar Clinical Research
Draper, Utah 84020
Contact:
Jane Bjorklund
801-369-4219
jane.bjorklund@numinusnetwork.com

Inner Space State Street
Orem, Utah 84058
Contact:
Janet Jimenez
801-871-5516
apply@innerspaceresearch.com

More Details

Status
Recruiting
Sponsor
Reunion Neuroscience Inc

Study Contact

Mark Pollack Chief Medical Officer, M.D.
1-888-880-REUN
info@reunionneuro.com